1 / 23

Systemic treatment for non- clear cell histology Alessandra Mosca Medical Oncology

Explore the efficacy of axitinib vs. sorafenib in non-clear cell RCC, including clinical trials, adverse events, and survival data. Understand the impact of histology on treatment outcomes. Updated information on ongoing clinical trials and a multidisciplinary approach to patient care.

metta
Download Presentation

Systemic treatment for non- clear cell histology Alessandra Mosca Medical Oncology

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Systemic treatment for non-clearcellhistology Alessandra Mosca MedicalOncology «Maggiore della Carità» University Hospital University of East Piedmont “A. Avogadro” Novara

  2. (+) (-) HIF, VEGF De Vita VT el al, 2005 Sporadic/hereditary (Sporadic)/hereditary (hereditary leiomyomatosis)

  3. Linehan et al, Annu Rev Med 2010

  4. Histology clear cell clear cell clear cell 124 pts (20%) non-clear cell clear cell clear cell clear cell Axitinib vs Sorafenib 723 2nd line PFS 6.7 vs 4.7 mo (p<0.0001) clearcell 8Rini BI et al, Lancet 2011

  5. CLINICAL TRIALS CONSIDERING NON-CLEAR CELL RCC

  6. NEW CLINICAL TRIALS FOR NON-CLEAR CELL RCC: COMPLETED -I-

  7. NEW CLINICAL TRIALS FOR NON-CLEAR CELL RCC: COMPLETED -II-

  8. NEW CLINICAL TRIALS FOR NON-CLEAR CELL RCC: ONGOING

  9. UP DATE FROM

  10. 894/2076 (43%) pts ineligible for clinical trials

  11. Adapted from Heng D et al, ASCO GU 2012

  12. Adapted from Heng D et al, ASCO GU 2012

  13. Adapted from Heng D et al, ASCO GU 2012

  14. Adapted from Heng D et al, ASCO GU 2012

  15. 25 non-clearcell 132 clearcell treated with TT: mediansurvival 15.4 mo (non-clear) vs 35 mo (clear) p=0.007 Non-clearcellhistology remains a significant and independent riskfactor for cancerspecificdeath for mRCCptstreated by TT

  16. 37 pts -> intermittent schedule 37 pts -> daily schedule Adverseevents: -Hypertension 50% -Pulmonaryembolism 11% -Fatigue 6.8% -Diarrhea 6.8%

  17. Adapted from Choueiri TK et al, ASCO GU 2012

  18. 67/74 ptsevaluable for both MET mutationand response to Foretinib: 5/10 (50%) ptswith germlineMET mutation: PR 5/10 (50%) ptswith germlineMET mutation: SD 5/57 (9%) ptswithout germlineMET mutation: PR 1/5 (20%) pts with somatic MET mutation: PR

  19. Sporadic papillary RCC is different from hereditary papillary RCC?

  20. CONCLUSIONS -I- Adapted from Cho D, ASCO GU 2012

  21. CONCLUSIONS -II- Adapted from Cho D, ASCO GU 2012

  22. CONCLUSIONS -III- Multidisciplinaryapproach to RCC patients (Pathologist, Urologist, Oncologist, Radiologist, Statistician, Nurse, …)

More Related